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Definition and causes of wheeze 
Approximately one in three children experience at 
least one episode of wheezing prior to their third 
birthday, and the cumulative prevalence of wheeze 
is almost 50% at the age of 6 yrs.1,2 Viral induced 
wheeze is by far the most common cause of 
recurrent early life wheeze, but other causes should 
also be considered. 
 
Table (1): Causes of recurrent wheeze in early 
life  
Prevalence Disease 
Common Viral bronchiolitis 
Asthma 






Uncommon Congenital heart disease 
Immunodeficiency 
Immotile cilia syndrome 






Modified from El-Gamal and El-Sayed 3 
 
Upper respiratory tract infections account for 
more than 80% of wheezing episodes in young 
children. Most children wheeze only when they 
have upper respiratory tract infections, are usually 
non-atopic, and outgrow symptoms by 6 years of 
age. Yet, since preschool-age children have 6 to 10 
upper respiratory tract infections each year, 
recurrent virus-induced wheezing is associated with 
considerable distress and use of health care 
services.4  
 
ICS in preschool wheeze 
Preschool children with wheeze have deficits in 
lung function at 6 years of age that persisted until 
early and middle adulthood. Daily inhaled 
corticosteroids seem to be the most effective 
therapy for recurrent wheezing in trials of children 
with interim symptoms or atopy. Intermittent high-
dose inhaled corticosteroids seem effective in 
moderate-to-severe viral-induced wheezing without 
interim symptoms.5  
In a meta-analysis, an improvement in asthma 
symptoms’ score and parental perceived QOL of 
children favored the ICS use. However, there was 
no statistical difference in hospitalization rates. 
Intermittent use of ICS was not associated with any 
significant increase in adverse events including 
growth suppression in preschool or school-aged 
children.6 
On the other hand, intermittent inhaled 
corticosteroids in infants with episodic wheezing 
did not prove efficacy in a clinical trial. There was 
no effect on the progression from episodic to 
persistent wheezing as well as no short-term effect 
on respiratory symptoms.7 Similarly, long-term 
effects of ICS for respiratory syncytial virus 
bronchiolitis were considered doubtful in a 
randomized placebo-controlled trial. At age 6, the 
mean FEV1 percentage, bronchial hyper-
responsiveness, physician-diagnosed asthma, and 
parent reported hay fever and eczema were 
comparable between both groups.8 
 
Predicting the response to treatment in wheezy 
children 
Asthma phenotypes could theoretically be used to 
predict treatment response.9 Characteristics of the 
asthma-predictive phenotype in early childhood 
include male sex, history of wheezing with lower 
respiratory tract infections, history of parental 
asthma, history of atopic dermatitis, eosinophilia, 
early sensitization to food or aeroallergens, and 
lower lung function in early life.10 
A study on long-term responses to inhaled anti-
inflammatory medications based on childhood 
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asthma phenotypes identified 5 reproducible patient 
clusters that could be differentiated on the basis of 3 
groups of features: atopic burden, degree of airway 
obstruction, and history of exacerbation. One 
cluster demonstrated a positive response to both 
budesonide and nedocromil compared with placebo, 
whereas the other cluster demonstrated minimal 
responses to both budesonide and nedocromil 
compared with placebo.11 
Phenotyping asthma by multivariate analyses 
and more recently by unsupervised analysis of 
children cohorts revealed three wheeze phenotypes 
in preschool age: the mild episodic viral wheeze 
phenotype; the multi-trigger atopic wheeze; and the 
less often encountered severe non-atopic wheeze. 
Early onset of allergy in asthma (more prevalent in 
boys) was associated with poor prognosis unlike the 
severe non-atopic wheeze phenotype which had a 
female predominance. The prognosis of the severe 
non-atopic wheeze depends on time of onset (early 
or late) of allergic expression.12 Remission was 
most frequently observed in mild early viral wheeze 
while persistence was observed in atopic multiple-
trigger wheeze and those with non-atopic 
uncontrolled wheeze developed severe uncontrolled 
wheeze in most cases.13  
 
Factors affecting response to ICS 
There is high inter individual variation in response 
to ICS as judged by the improvement in lung 
function, increase in the number of symptom-free 
days, and reductions in exacerbations and 
hospitalizations. Using pharmacogenomic 
approaches, several promising candidate genes 
associated with response to ICSs have been 
identified.14 
Obesity might hinder response to ICS. In one 
trial, overweight/obese children in the Childhood 
Asthma Management Program (CAMP) showed a 
decreased response to inhaled budesonide on 
emergency department visits or hospitalizations for 
asthma.15 In utero smoke (IUS) exposure reduces 
age-related improvements in airway responsiveness 
among children with asthma. It appears to blunt the 
beneficial effects of ICS use on airways 
responsiveness.16 
 
There are factors that affect the delivery of ICS in 
infants and young children17 
• Anatomy and physiology: the pharynx and 
supraglottic area are less rigid, epiglottis is 
narrow, floppy, and closer to the palate, and the 
larynx is higher and very close to the base of the 
tongue. 
• Lung deposition: infants are unable to hold their 
breath, and therefore a greater proportion of the 
inhaled medication is likely to be exhaled. 
• Behavior and adherence: the fit of the face mask, 
squirming and crying during aerosol 
administration, and general acceptance of 
treatment. 
• Face-mask seal and design: even a 1-cm gap 
between the mask and the face reduced the dose 
delivered to the respiratory tract by 50% 18  
• Crying: it affects not only the breathing patterns 
of infants but also the adequacy of the seal 
between the mask and face. 
• Inhaled particle size: small particles increased 
lung deposition and reduced oropharyngeal 
deposition. 
 
Adherence to ICS Therapy 
Poor adherence may persist in children despite a 
high level of concordance between medical team 
and parents, even in the absence of socio-economic 
barriers. In an ancillary study, adherence was 
assessed by using self-reported and objective data 
in 5- to 12-year-old children with mild or moderate 
asthma. A significant decrease occurred in the 
yearly mean adherence based on objective data 
(from 69% in year 1 to 52% in year 4). A 
significant, although smaller, decrease also 
occurred in mean adherence based on self-report.19 
 
Adverse effects of ICS 
Adverse effects resulting from the use of ICS are 
often underestimated in daily clinical practice. 
Although ICS treatment is generally considered 
safe in children, the potential adverse effects related 
to its regular use have been and continue to be a 
matter of concern. ICS are reported to cause some 
local and systemic adverse effects (Table 2). This 
seems to be dose-dependent being most common in 
individuals receiving high dose ICS with or without 
oral corticosteroids (OCS).20 
 
Effect on growth 
Use of ICS for >12 months in children with asthma 
has a limited impact on annual growth velocity. 
Among ICS users in one study, there was a slight 
reduction of about one cm in final adult height 
which when interpreted in the context of average 
adult height in England represented a 0.7% 
reduction compared to non-ICS users.21 An 
evidence-based analysis revealed that there is 
ICS dose-dependent reduction in growth velocity in 
prepubescent school-aged children with mild to 
moderate persistent asthma. The choice of ICS 
molecule (mometasone, ciclesonide or fluticasone) 
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Table (2): Potential local and systemic side 









Suppressed HPA-axis function 
Adrenal crisis (with insufficiency) 
Suppressed growth velocity 
Decreased lower-leg length 
Reduced bone mineral density 







HPA-axis: hypothalamic pituitary adrenal axis 
 
 
Effect on adrenal functions 
Patients at risk of adrenal suppression (AS) and 
would benefit from screening include: 23 
• Patients who have symptoms of AS regardless of 
ICS dose 
• Patients who are on higher doses of ICS (≥400 
mcg of fluticasone or equivalent) 
• Concomitant use of oral steroids 
• Concomitant use of ritonavir or ketoconazole 
• Recurrent respiratory infections with slow 
recovery 
• Any planned surgical procedure 
• Poor growth or unexplained hypoglycemia 
• Gastroenteritis, chronic nausea and vomiting, 
dehydration 
• Any other serious medical/surgical illness 
• Heat stress, any condition where AI might result 
in acute adrenal crisis 
 
Effect on bone mineral accretion 
Long-term therapy with ICS therapy is safer than 
frequent bursts of oral corticosteroids on bone 
mineral status. Nutritional supplementation (e.g. 
calcium and vitamin D) should blunt the effects of 
CS on bone mineral density. The potential adverse 
effects of ICS need to be weighed against the 
benefit of these drugs to control persistent asthma. 
ICS therapy should always aim to reach the lowest 





• The intermittent use of ICS in infants with 
episodic wheezing is still controversial and 
needs further investigations to validate 
• Asthma phenotypes could theoretically be used 
to predict ICS treatment response 
• Other potential predictors of the response to ICS 
include several genes, the body mass index, air 
pollution, and inutero smoke exposure  
• Some anatomic features of the airways in infants 
may hinder the effect of ICS as well as other 
factors including crying, face mask fitting, and 
adherence to therapy 
• Use of ICS for >12 months in children with 
asthma has a limited impact on annual growth 
velocity. 
• Long-term therapy with ICS therapy is safer 
than frequent bursts of oral corticosteroids on 
bone mineral status 
• ICS therapy should always aim to reach the 
lowest effective dose  
• The potential adverse effects of ICS need to be 
weighed against the benefit of these drugs to 
control persistent asthma.  
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